Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.49 |
| ▸ | LMNA | P02545 | 4/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | PPARG | P37231 | 2/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | JAK2 | O60674 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.41 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | USP2 | O75604 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 3/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3853534 | 0.92 | ALDH1A1 (0.47) | ALDH1A1LMNAKDM4ESMN1; SMN2MEN1 | |
| SCHEMBL3855997 | 0.90 | ALDH1A1 (0.45) | ALDH1A1LMNAKDM4ESMN1; SMN2MEN1 | |
| SCHEMBL3850428 | 0.88 | ALDH1A1 (0.50) | ALDH1A1LMNAKDM4ESMN1; SMN2MEN1 | |
| SCHEMBL3849126 | 0.84 | ALDH1A1 (0.41) | ALDH1A1LMNAKDM4ESMN1; SMN2MEN1 | |
| SCHEMBL3856749 | 0.83 | SMN1; SMN2 (0.43) | ALDH1A1LMNAKDM4ESMN1; SMN2MEN1 | |
| SCHEMBL3849080 | 0.82 | PDE4B (0.42) | ALDH1A1LMNAKDM4ESMN1; SMN2MEN1 | |
| SCHEMBL3851808 | 0.82 | ALDH1A1 (0.42) | ALDH1A1LMNAKDM4EMEN1KMT2A | |
| SCHEMBL3847603 | 0.82 | DPP4 (0.40) | ALDH1A1LMNAKDM4EMEN1KMT2A | |
| SCHEMBL3853119 | 0.81 | MAPK1 (0.55) | ALDH1A1LMNAKDM4ESMN1; SMN2MEN1 | |
| SCHEMBL3846967 | 0.80 | EGLN3 (0.50) | ALDH1A1LMNASMN1; SMN2PPARGJAK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2889289-A1 | Pyridazine-dione N-substituted glycine derivatives as HIF hydroxylase inhibitors | GlaxoSmithKline LLC (US) | 2015-07-01 | — | — | EP | disclosed |
| US-RE44613-E1 | N-substituted glycine derivatives: hydroxylase inhibitors | GLAXOSMITHKLINE LLC (US) | 2013-11-26 | — | — | US | disclosed |
| US-7608621-B2 | Such as n-{[2-[(4-bromo-2-fluorophenyl)methyl]-5-hydroxy-6-(1-methylethyl)-3-oxo-2,3-dihydro-4-pyridazinyl]carbonyl}glycine; anemia; increasing erythropoietin production | SMITHKLINE BEECHAM, CORP. (US) | 2009-10-27 | — | — | US | disclosed |
| US-20080214549-A1 | N-Substituted Glycine Derivatives: Hydroxylase Inhibitors | GLAXOSMITHKLINE LLC | 2008-09-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080214549-A1 | N-Substituted Glycine Derivatives: Hydroxylase Inhibitors | EGLN2, EGLN3, HIF1AN | ALDH1A1 564/4885LMNA 2802/4885KDM4E 527/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.